+Vote!
Medical News Today (Free subscription) | yesterday
SNM will hold its Conjoint Mid-Winter Meetings Jan. 27-Feb. 2, 2010, at the Albuquerque Convention Center in Albuquerque, N.M. This year, SNM joins its annual Mid-Winter Educational Symposium with the 2010 Annual Meeting and Educational Symposium of the American College of Nuclear Medicine (ACNM), the Nanomedicine and Molecular Imaging Summit and the Clinical Trials Network Community Workshop.
4Vote!
Medical News Today (Free subscription) | 25/11/2009
UK-based Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials, recruited the highest number of patients to the South African study investigating a paediatric vaccine against rotavirus. The company recruited more than 2000 children aged between 5 and 10 weeks in 3 months, making Synexus the largest single source of subjects for this Phase III...
4Vote!
Medical News Today (Free subscription) | 25/11/2009
OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the EDC marketplace, announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study. The 3-year, 10-site study is planning to enroll 340 subjects. "After a careful...
4Vote!
Medical News Today (Free subscription) | 25/11/2009
Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal).
4Vote!
Medical News Today (Free subscription) | 24/11/2009
Women who store fat on their waist in middle age are more than twice as likely to develop dementia when they get older, reveals a new study from the Sahlgrenska Academy. The study has just been published in the scientific journal Neurology. "Anyone carrying a lot of fat around the middle is at greater risk of dying prematurely due to a heart attack or stroke," says Deborah Gustafson, senior...
3Vote!
Rocky Mount Telegram - Business (Free subscription) | 23/11/2009
NEW YORK — Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical ...
4Vote!
Medical News Today (Free subscription) | 23/11/2009
POZEN Inc. (NASDAQ: POZN) announced the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
4Vote!
Medical News Today (Free subscription) | 23/11/2009
ImmuPharma PLC announced the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
4Vote!
Medical News Today (Free subscription) | 23/11/2009
Treatment that includes medication plus a structured training program for parents reduces serious behavioral problems in children with autism and related conditions, according to a study funded by the National Institute of Mental Health (NIMH). The study, which was part of the NIMH Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, was published in the December 2009 issue of the...
4Vote!
Medical News Today (Free subscription) | 23/11/2009
A pediatric immunologist at The Children's Hospital of Philadelphia has received a prestigious annual award from the American Philosophical Society, an organization founded in 1743 by Benjamin Franklin. Jordan S. Orange, M.D., Ph.D., received the Society's Judson Daland Prize for his contributions to research and treatment of inherited immune deficiency diseases. The Judson Daland Prize for Clinical...
4Vote!
Medical News Today (Free subscription) | 23/11/2009
An article published Online First in The Lancet Oncology reports that bevacizumab given in addition to the combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) is well tolerated. In addition, it shows promising antitumor activity in patients with advanced biliary-tract cancers. The article reviews the survival and tumour response that compare favourably with earlier studies in patients...
4Vote!
Medical News Today (Free subscription) | 23/11/2009
Emergency medical service (EMS) providers in the United States assess an estimated 350,000 cardiac arrests each year. Only 5 to 10 percent of people who have sudden cardiac arrest survive. Better quality cardiopulmonary resuscitation (CPR) provided by prehospital EMS providers may be associated with better patient outcome. The Resuscitation Outcomes Consortium (ROC) is the largest clinical research...
4Vote!
Medical News Today (Free subscription) | 22/11/2009
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has adopted a negative opinion for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, advanced or metastatic non-small cell lung cancer (NSCLC).
4Vote!
Medical News Today (Free subscription) | 22/11/2009
Sanofi-aventis ( EURONEXT: SAN and NYSE: SNY) and Medicines for Malaria Venture (MMV) announced that they have entered an agreement to launch the largest safety and efficacy study of an antimalarial drug. This field-monitoring program on ASAQ, a fixed-dose combination of artesunate and amodiaquine, started in Côte d'Ivoire in October 2009. MMV is a not-for-profit drug research and development...
4Vote!
Medical News Today (Free subscription) | 22/11/2009
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the a